The immunologic basis for the treatment of psoriasis with new biologic agents.

By J. Krueger. Journal of American Academy of Dermatology, 2002

646 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model (2005, background): “In addition to these changes, keratinocytes may produce increased levels of chemokines or integrins whose transcription is upregulated by activated Stat3, further aiding T-cell migration and adherence to the epidermi”
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. (2005, background): “Although the cause of psoriasis remains unknown, the evolving evidence suggests that psoriasis is a complex disorder caused by the interaction of multiple genes, the immune system, and environmental factors.(3,4) A recent population-based survey in the United States estimated the lifetime prevalence”
Etanercept as monotherapy in patients with psoriasis. (2003, neutral): “3 41 (25) 56 (35) 34 (21) 23 (14) 35 (22) 35 (22) 22 (13)”
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris (2004, background): “Accumulating evidence supports the role of type 1 T cells and IFN- in the pathogenesis of psoriasis (8).”